JP2004505940A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004505940A5 JP2004505940A5 JP2002517470A JP2002517470A JP2004505940A5 JP 2004505940 A5 JP2004505940 A5 JP 2004505940A5 JP 2002517470 A JP2002517470 A JP 2002517470A JP 2002517470 A JP2002517470 A JP 2002517470A JP 2004505940 A5 JP2004505940 A5 JP 2004505940A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- alkyl
- halogen
- compound according
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 206010026749 Mania Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021030 Hypomania Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- -1 cyanoguanidino Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0019008.2A GB0019008D0 (en) | 2000-08-04 | 2000-08-04 | Therapeutic compounds |
| PCT/SE2001/001687 WO2002012168A1 (en) | 2000-08-04 | 2001-07-31 | Novel n-(2-phenyl-3-aminopropyl)naphtamides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004505940A JP2004505940A (ja) | 2004-02-26 |
| JP2004505940A5 true JP2004505940A5 (enExample) | 2008-09-04 |
Family
ID=9896866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002517470A Pending JP2004505940A (ja) | 2000-08-04 | 2001-07-31 | 新規なｎ−（２−フェニル−３−アミノプロピル）ナフトアミド |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6963011B2 (enExample) |
| EP (1) | EP1307425B1 (enExample) |
| JP (1) | JP2004505940A (enExample) |
| KR (1) | KR20030059089A (enExample) |
| CN (1) | CN1444558A (enExample) |
| AT (1) | ATE293591T1 (enExample) |
| AU (1) | AU2001284568A1 (enExample) |
| BR (1) | BR0112957A (enExample) |
| CA (1) | CA2415467A1 (enExample) |
| DE (1) | DE60110233T2 (enExample) |
| GB (1) | GB0019008D0 (enExample) |
| IL (1) | IL153784A0 (enExample) |
| MX (1) | MXPA03000977A (enExample) |
| NO (1) | NO20030509L (enExample) |
| NZ (1) | NZ523434A (enExample) |
| WO (1) | WO2002012168A1 (enExample) |
| ZA (1) | ZA200300218B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003077847A2 (en) | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Substituted amides |
| US20050154202A1 (en) * | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
| SE0201938D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New process |
| WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| CA2740970A1 (en) | 2008-10-21 | 2010-04-29 | Oregon Health & Science University | Naphthamides as anticancer agents |
| CN116102514B (zh) * | 2023-01-17 | 2024-03-15 | 河南省锐达医药科技有限公司 | 一类萘酰胺类化合物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751327A (en) * | 1985-06-28 | 1988-06-14 | Xerox Corporation | Photoconductive imaging members with unsymmetrical squaraine compounds |
| AU6578090A (en) * | 1989-11-06 | 1991-05-09 | Warner-Lambert Company | Acat inhibitors |
| CA2037153A1 (en) * | 1990-03-09 | 1991-09-10 | Leo Alig | Acetic acid derivatives |
| GB9922521D0 (en) * | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
| GB9907571D0 (en) * | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
| FR2792835B3 (fr) * | 1999-04-27 | 2001-05-25 | Sanofi Sa | Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression |
-
2000
- 2000-08-04 GB GBGB0019008.2A patent/GB0019008D0/en not_active Ceased
-
2001
- 2001-07-31 JP JP2002517470A patent/JP2004505940A/ja active Pending
- 2001-07-31 DE DE60110233T patent/DE60110233T2/de not_active Expired - Fee Related
- 2001-07-31 IL IL15378401A patent/IL153784A0/xx unknown
- 2001-07-31 CA CA002415467A patent/CA2415467A1/en not_active Abandoned
- 2001-07-31 BR BR0112957-0A patent/BR0112957A/pt not_active IP Right Cessation
- 2001-07-31 EP EP01963637A patent/EP1307425B1/en not_active Expired - Lifetime
- 2001-07-31 AU AU2001284568A patent/AU2001284568A1/en not_active Abandoned
- 2001-07-31 CN CN01813656A patent/CN1444558A/zh active Pending
- 2001-07-31 US US10/333,658 patent/US6963011B2/en not_active Expired - Fee Related
- 2001-07-31 NZ NZ523434A patent/NZ523434A/en unknown
- 2001-07-31 AT AT01963637T patent/ATE293591T1/de not_active IP Right Cessation
- 2001-07-31 WO PCT/SE2001/001687 patent/WO2002012168A1/en not_active Ceased
- 2001-07-31 KR KR10-2003-7001532A patent/KR20030059089A/ko not_active Withdrawn
- 2001-07-31 MX MXPA03000977A patent/MXPA03000977A/es active IP Right Grant
-
2003
- 2003-01-08 ZA ZA200300218A patent/ZA200300218B/xx unknown
- 2003-01-31 NO NO20030509A patent/NO20030509L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517087A5 (enExample) | ||
| JP2004534816A5 (enExample) | ||
| JP2005511698A5 (enExample) | ||
| JP2018188483A5 (enExample) | ||
| JP2011500658A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2004526788A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| JP2006514626A5 (enExample) | ||
| JP2003511384A5 (enExample) | ||
| NO20072664L (no) | Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser | |
| JP2010524914A5 (enExample) | ||
| JP2005508349A5 (enExample) | ||
| JP2006503845A5 (enExample) | ||
| JP2004500426A5 (enExample) | ||
| JP2001510843A5 (enExample) | ||
| JP2005525323A5 (enExample) | ||
| JP2004505940A5 (enExample) | ||
| JP2002526410A5 (enExample) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2020511536A5 (enExample) | ||
| JP2004504308A5 (enExample) | ||
| JP2004530691A5 (enExample) | ||
| JP2004509954A5 (enExample) | ||
| JP2007515467A5 (enExample) |